Navigation Links
Wyeth Announces Election of Timothy P. Cost as Senior Vice President, Corporate Affairs
Date:2/5/2008

MADISON, N.J., Feb. 5 /PRNewswire-FirstCall/ -- Wyeth (NYSE: WYE) today announced that its Board of Directors has elected Timothy P. Cost, 48, to the position of Senior Vice President, Corporate Affairs effective immediately. Mr. Cost replaces Marily H. Rhudy, 59, who has announced her plans to retire.

Prior to joining Wyeth, Mr. Cost was Executive Vice President, Corporate Affairs at ARAMARK since 2003. During his 27-year career, he has served in senior executive roles for several leading companies. He formerly was Senior Vice President of Corporate Affairs for Pharmacia and, prior to that, Vice President of Investor Relations and Corporate Intelligence for Bristol-Myers Squibb Company. He also served as Senior Vice President, Communications and Strategy for Centocor, Inc. Mr. Cost began his career with Kodak, holding a number of management positions with the company, including Director of Strategic Planning, Worldwide Operations and Vice President, Investor Relations.

Mr. Cost earned his undergraduate degree from Jacksonville University in Florida and holds an M.B.A. in Finance and Economics from the William E. Simon Graduate School of Business at the University of Rochester.

"I am pleased to have a leader of Tim's caliber joining the senior management team," says Bernard Poussot, President and Chief Executive Officer, Wyeth. "His extensive and broad experience, especially in the biotechnology and pharmaceutical sectors, will help us as we continue to deliver innovative new products and navigate the changing business environment."

Ms. Rhudy joined Wyeth in 1993 as Assistant Vice President, Professional Relations for Wyeth's pharmaceuticals division and held positions of increasing responsibility while building
'/>"/>

SOURCE Wyeth
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Wyeth to Present at the Merrill Lynch 2008 Global Pharmaceutical, Biotechnology and Medical Device Conference
2. Wyeth Reports Earnings Results for the 2007 Fourth Quarter and Full Year
3. Wyeth Consumer Healthcare Supports U.S. Food and Drug Administration Decision for Over-the-Counter Cough and Cold Medications in Children under Two Years of Age
4. Wyeth Will Pursue Claim for Damages Resulting From Teva Pharmaceuticals Launch of Generic Pantoprazole in Violation of PROTONIX Patent
5. Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharmas Fall Line Up!
6. Wyeth Provides Update on Regulatory Review of Viviant (bazedoxifene)
7. Raven biotechnologies, inc. and Wyeth Pharmaceuticals Extend Evaluation Period of Selected Raven Antibodies
8. Wyeth Declares Preferred Stock Dividend
9. Wyeth Announces Election of New Principal Corporate Officer
10. Wyeth Pharmaceuticals Acquires Haptogen Ltd. to Boost Biotechnology Drug Discovery
11. Wyeth Announces $5 Billion Share Repurchase Program; Declares Increase in Common Stock Dividend

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)...ntries have an opportunity to take the lead in two... University of Valencia (UV), working together wit...ive fabric of the Spanish biotechnology industry. ...ctors have more clout than those in English-speaki... and plants has been overlooked by the leading cou...
(Date:11/20/2009)...November 20 Karolinska Development...und (EIF) has entered into a,co-investment agreeme...e,managed by Karolinska Development and used to in...rmaceutical and medical technology companies. EIF,...ment fund. The agreement,represents EIF,s largest ...
(Date:11/19/2009)...be able to charge their cell phones and other pers...nt discovery made by UC San Diego engineers could ... could do just this. , In recent research, publ...aru, a professor in the UCSD Department of Mechani... student Mark Hoefer, have found that artificially...
(Date:11/19/2009)...A, Md., Nov. 19 Spherix ...technology for diabetes therapy, and a provider of...ood, supplement, biotechnology and pharmaceutical ...y reported $6.3 million registered direct placemen...f its common stock and warrants to purchase up to ...
Breaking Biology Technology:Spanish biotechnology should focus on food and plant sectors to be more competitive 2Karolinska Development and EIF Start Landmark Co-Investment Fund for Life Science Innovation 2Karolinska Development and EIF Start Landmark Co-Investment Fund for Life Science Innovation 3Nanotube defects equal better energy and storage systems 2Spherix Announces the Closing of $6.3 Million Registered Direct Offering 2Spherix Announces the Closing of $6.3 Million Registered Direct Offering 3
...SE II DATA FOR LEAD DRUG CANDIDATE ARIKACE(TM) DRI...ON, N.J., Oct. 2 Transave, Inc., a,biopharmaceuti...ed,pharmaceuticals for the site-specific treatment...has secured a $12.5 million venture loan from CIT,..., an affiliate of Horizon,Technology Finance Manag...
...en children,s hospitals in nation selected as Top ...roup, PITTSBURGH, Oct. 2 Children,s Hospital of ... hospitals in the nation to have been,selected as ...t evaluates,patient safety at more than 1,220 part...nition was based on the results of the 2008,Leapfr...
...., Oct. 2 Pacira Pharmaceuticals, Inc.,an acute c...ced the,addition of a key senior executive to the ...oins Pacira as Vice President of Medical Education...sly with inVentiv Health where,he held several sen...,serving on their Executive Team as president of T...
Other Biology Technology:Transave, Inc. Secures $12.5 Million in New Financing 2Transave, Inc. Secures $12.5 Million in New Financing 3Transave, Inc. Secures $12.5 Million in New Financing 4Transave, Inc. Secures $12.5 Million in New Financing 5Children's Hospital of Pittsburgh of UPMC Receives Prestigious Recognition for Patient Safety Efforts in National Survey 2Children's Hospital of Pittsburgh of UPMC Receives Prestigious Recognition for Patient Safety Efforts in National Survey 3Pacira Pharmaceuticals, Inc. Adds Experienced Physician Dr. David St. Peter to Leadership Team 2
(Date:11/20/2009)...ontribute their abstracts to the World Congress on... global meeting devoted to all aspects of osteopor... The Congress will be held in Florence, Italy from... be submitted online at http://www.iofwco-ecceo10...2010. , IOF and ESCEO are pleased to announce th...
(Date:11/20/2009)...ingle bacterial gene into yeast, researchers from ...achieved three improvements in bioethanol producti..., less acetate and elimination of the major by-pro...ed in the scientific journal Applied and Environm... is made by the yeast Saccharomyces cerevisiae fro...
(Date:11/20/2009)...esearch Center (ERC) has been awarded a grant from...thods of recovering and reusing the heat that woul...ession process in a carbon capture system. The goa...capture and sequestration, or storage (CCS), and t...mitted into the atmosphere by coal-fired power pla...
Breaking Biology News(10 mins):Special sessions announced for World Congress on Osteoporosis 2010 - IOF WCO - ECCEO10 2Special sessions announced for World Congress on Osteoporosis 2010 - IOF WCO - ECCEO10 3Delft breakthrough in bioethanol production from agricultural waste 2Lehigh receives grant to reduce cost of carbon capture at coal-fired power plants 2Lehigh receives grant to reduce cost of carbon capture at coal-fired power plants 3Announcing Companies to Present at the 7th Annual MidAmerica Healthcare Venture Forum 5079 1Announcing Companies to Present at the 7th Annual MidAmerica Healthcare Venture Forum 5079 2Announcing Companies to Present at the 7th Annual MidAmerica Healthcare Venture Forum 5079 3Announcing Companies to Present at the 7th Annual MidAmerica Healthcare Venture Forum 5079 4AFGE Expresses Concern Over FEHBP Premium Increases 58493 1Cadence Pharmaceuticals CEO Ted Schroeder to Present at the JMP Securities Healthcare Focus Conference in New York on October 6 2009 58489 1
...DELPHIAMagnetic resonance imaging (MRI) isn,t just...my. Thanks to novel imaging reagents and technolog...t Eric Ahrens, MRI can be used to visualize with ...est in the living body. The ability to non-invasiv...will greatly aid the study and treatment of cancer...
...stor Spark Capital Leads Round with Additional Fun... from Existing Investors Including Lockheed Mar...s., NEW YORK, Aug. 20 Clear(R), the fast pass fo...enture funding. Led by new investor,Spark Capital,... Venture,Partners, and existing investors Lockheed...
... pain treatments which contain codeine may be risk...earchers at The University of Western Ontario, and...nto.,Lead author Dr. Gideon Koren published resear...eutics which suggests that the codeine used in so... even fatal results for infants when ingested by s...
Other Biology News:Carnegie Mellon MRI technology that non-invasively locates, quantifies specific cells in the body 2Carnegie Mellon MRI technology that non-invasively locates, quantifies specific cells in the body 3Clear(R) Secures $44.4 Million in Venture Funding 2Clear(R) Secures $44.4 Million in Venture Funding 3Codeine not safe for all breastfeeding moms and their babies 2
Goat Anti-PITPN Antibody, Unconjugated from Raybiotech, Inc.
Rat Anti-Mouse CD205 (DEC-205) Monoclonal Antibody, Unconjugated, Clone NLDC-145 from Cell Sciences
Rabbit Anti-Human MT3-MMP Membrane-Type Metalloproteinase-3, propeptide domain, Antibody, Unconjugated from CEDARLANE Laboratories Limited
Mouse Anti-Human gp340 Monoclonal Antibody, Unconjugated, Clone HYB213-01 from MBL International
Biology Products: